Amylyx Pharmaceuticals, Inc.
AMLXHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned May 30, 2026
Scan Results
Daily timeframeAmylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the. With a market capitalization of $1.60B, it sits in small-cap territory. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Market Cap
$1.60B
Beta
-0.10
P/E (TTM)
—
P/E (Fwd)
-11.33
EPS (TTM)
$-1.48
EPS (Fwd)
$-1.27
ROE
-63.3%
ROA
-38.8%
Cash
$279.8M
Total Debt
$5.6M
Free CF
-$71.5M
52W Change
181.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $279.8M in cash comfortably exceeding the $5.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$71.5M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -63.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $22.2M (2022) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, Amylyx Pharmaceuticals, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, AMLX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing AMLX.